2022-04-14 | NDAQ: EYES | Press release
Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight”), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., co -founder and CEO of Nano Precision Medical, Inc. (“NPM”), will air on The RedChip Money Report® on Bloomberg US on April 16 at 7 p.m. Eastern Time (ET).Bloomberg US is available in approximately 73 million homes across the United States.
As previously announced, Second Sight and NPM have entered into a definitive agreement under which privately held NPM will merge with a wholly owned subsidiary of Second Sight in an all-stock transaction. NPM will be the surviving company and will be owned by Second Sight. The resulting company will focus on developing innovative drugs and medical implants that address chronic diseases with high unmet medical need.
To view the interview segment, please visit: https://youtu.be/QaxKGcSt610
The RedChip® Money Report is produced by RedChip Companies Inc., an international investor relations and media firm with 30 years’ experience focused on Discover the Blue Chips of tomorrow today™. “The RedChip Money Report®” provides insightful commentary on small cap investing, interviews with Wall Street analysts, reviews of financial books, as well as interviews with public company executives.
About Second Sight Medical Products, Inc.
Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable vision prostheses to provide useful artificial vision to people who are blind. A recognized world leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of visually impaired people. The company’s headquarters are located in Los Angeles, California.
About Nano Precision Medical Products, Inc.
Nano medical precision. Inc is a privately held biopharmaceutical company that develops drug implants leveraging the company’s proprietary NanoPortal drug implant technology. These drug implants, designed to provide minimally fluctuating drug profiles, will address medication nonadherence, which is a primary reason for the suboptimal clinical benefits associated with oral and injectable products that treat chronic disease. The Company’s lead product, NPM-119, is a GLP-1 receptor agonist in development to treat patients with type 2 diabetes. The Company is headquartered in Emeryville, California. More information is available at www.nanoprecisionmedical.com.
This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate events or future trends or which are not statements of historical matters. Examples of forward-looking statements include, but are not limited to, statements made in this press release regarding the proposed merger, including the benefits of the proposed business combination, integration plans, expected synergies and opportunities, management and governance expected of the combined company, and the expected timing of the proposed transactions contemplated by the definitive merger agreement. Forward-looking statements are neither historical facts nor guarantees of future performance. Instead, they are based solely on Second Sight and NPM’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are beyond our control. Actual outcomes and results may differ materially from those indicated in the forward-looking statements. Accordingly, you should not rely on any such forward-looking statements. Important factors that could cause actual results and results to differ materially from those set forth in the forward-looking statements include, among others, the following: (1) the occurrence of any event, change or other circumstance that could cause termination of the Merger Agreement or otherwise prevent the Merger Transaction from closing; (2) the outcome of any legal proceedings that may be brought against Second Sight or NPM following the announcement of the Merger, (3) the inability to complete the Merger, including due to the inability to obtain approval by Second Sight or NPM shareholders, or failure to satisfy any of the other conditions to closing of the merger agreement, (4) receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the business combination; (5) the inability to obtain a listing of the common stock of the post-merger company on the Nasdaq stock exchange following the merger; (6) the risk that the announcement and completion of the business combination will disrupt ongoing plans and operations; (7) the ability to recognize the expected benefits of the merger, which may be affected by, among other things, competition, the ability of the combined company to grow and manage the growth profitably and to retain its key employees; (8) merger transaction costs; (9) changes in applicable laws or regulations; (10) the possibility that Second Sight and/or NPM will be adversely affected by other economic, business, regulatory and/or competitive factors; (11) the impact of COVID-19 on Second Sight’s and/or NPM’s business and (12) our ability to obtain adequate financing to fund our business operations in the future; and (13) other risks and uncertainties disclosed from time to time in the proxy statement to be filed regarding the business combination, including those under “Risk Factors” in this and other documents filed by Second Sight with the SEC. Some of these risks and uncertainties may in the future be amplified by the COVID-19 outbreak and there may be additional risks that Second Sight considers immaterial or which are unknown. A more detailed list and description of risks and uncertainties can be found in Second Sight’s Annual Report on Form 10-K, filed March 29, 2022. Any forward-looking statements we make in this press release are based solely on information currently available to Second Sight and speaks only as of the date it is made. Second Sight undertakes no obligation to update publicly any forward-looking statements, written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law. required.